Here’s a shocker—having TNBC plus the BRCA mutation is actually better than not having the mutation. That’s certainly contrary to contemporary wisdom. Here’s the story:
• Of 77 women with triple-negative breast cancer treated at the M.D. Anderson Cancer Center, 15 had BRCA mutations—12 with BRCA1 and three with BRCA2.
• All were treated between 1987 and 2006.
• The five-year relapse-free rate for patients with the mutation was 86.2 percent. For patients without the mutation, it was 51.7 percent.
• The five-year overall survival rate for patients with the mutation was 73.3 percent. For patients without the mutation, it was 52.8 percent.
Many of the patients did not know they had the mutation because they had not done genetic testing.
Ana M. Gonzalez-Angulo, M.D., associate professor in MD Anderson’s Departments of Breast Medical Oncology and Systems Biology presented the findings in advance of the 2010 Breast Cancer Symposium. A news release from M.D. Anderson provides additional perspective.